Clinical Trials Logo

Clinical Trial Summary

The OPTIMISE study is a prospective, multi-center, multi-national, structured data collection initiative, first compiling data on the current treatment of post myocardial infarction patients (screening-log) and then, prospectively evaluating only those patients being prescribed Omacor as part of their standard secondary prevention treatment. The aim is to observe the Omacor cohort of patients for a period of 12 months, collecting long term observational data as clinical and patient-reported outcomes, especially, but not exclusively, recurrent non fatal Myocardial Infarction (MI), sudden death, or new Congestive Heart Failure (CHF). No predefined additional visits, medical tests, labs, procedures or interventions will be mandated. Only results from routinely performed tests, labs, procedures and/or interventions will be collected if available.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01632878
Study type Observational
Source Viatris Inc.
Contact
Status Completed
Phase
Start date July 2012
Completion date December 2014

See also
  Status Clinical Trial Phase
Completed NCT04568083 - Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice
Completed NCT01405287 - Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT Phase 2
Recruiting NCT01226225 - A Multicentre Trial on the Effectiveness of Physical Rehabilitation of Patients With Coronary Artery Disease: Aerobic Interval Training Versus Moderate Continuous Training. Phase 3
Completed NCT02341664 - Patient and Provider Assessment of Lipid Management Registry
Terminated NCT00305162 - A Clinical Trial to Demonstrate the Efficacy of Cangrelor Phase 3